These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38591703)

  • 1. A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    Qian H; Chi C; Tricard T; Zhu Y; Dong L; Wang Y; Sha J; Wang J; Ma Z; Wang Y; Liu J; Dong B; Pan J; Xue W
    J Urol; 2024 May; 211(5):648-655. PubMed ID: 38591703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    Eastham JA; Heller G; Halabi S; Monk JP; Beltran H; Gleave M; Evans CP; Clinton SK; Szmulewitz RZ; Coleman J; Hillman DW; Watt CR; George S; Sanda MG; Hahn OM; Taplin ME; Parsons JK; Mohler JL; Small EJ; Morris MJ
    J Clin Oncol; 2020 Sep; 38(26):3042-3050. PubMed ID: 32706639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
    Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
    J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis.
    Chi C; Fan L; Dong B; Zhu Y; Xin Z; Pan J; Xue W
    Clin Genitourin Cancer; 2021 Aug; 19(4):e223-e234. PubMed ID: 33824096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Wang Y; Wu G; Fan L; Pan J; Gong Y; Fei X; Du X; Zhu Y; Xue W
    Prostate; 2021 Jun; 81(8):463-468. PubMed ID: 33822399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
    Narita S; Nara T; Kanda S; Numakura K; Saito M; Inoue T; Satoh S; Nanjo H; Tsuchiya N; Mitsuzuka K; Koie T; Kawamura S; Ohyama C; Tochigi T; Arai Y; Habuchi T
    Clin Genitourin Cancer; 2019 Feb; 17(1):e113-e122. PubMed ID: 30391137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer.
    Sasaki T; Nishikawa K; Kato M; Masui S; Yoshio Y; Sugimura Y; Inoue T
    Med Sci (Basel); 2021 Apr; 9(2):. PubMed ID: 33918590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
    Sumiyoshi T; Wang X; Warner EW; Sboner A; Annala M; Sigouros M; Beja K; Mizuno K; Ku S; Fazli L; Eastham J; Taplin ME; Simko J; Halabi S; Morris MJ; Gleave ME; Wyatt AW; Beltran H
    J Natl Cancer Inst; 2024 Jan; 116(1):115-126. PubMed ID: 37676819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits.
    Zhu Y; Fan L; Zhu H; Gong Y; Chi C; Wang Y; Pan J; Dong B; Xue W
    Front Oncol; 2023; 13():963411. PubMed ID: 37265786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination approach using neoadjuvant therapy with radical prostatectomy for improving oncological outcomes of high-risk prostate cancer: a narrative review.
    Nakane K; Kawase M; Kato D; Iinuma K; Kawase K; Takeuchi S; Tobisawa Y; Ito T; Koie T
    Transl Cancer Res; 2024 Jul; 13(7):3889-3897. PubMed ID: 39145084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-head comparisons of [
    Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis.
    Liu W; Yao Y; Liu X; Liu Y; Zhang GM
    Asian J Androl; 2021; 23(4):429-436. PubMed ID: 33586699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy.
    Oishi T; Hatakeyama S; Tabata R; Fujimori D; Fukuda M; Shinozaki T; Ishii N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Sato S; Ohyama C
    Sci Rep; 2023 Mar; 13(1):3436. PubMed ID: 36859718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
    Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.